Lactoferrin docking NIR-II cyanine dye as a potentiated phototheranostic for synchronous multimodal bioimaging and tumor photo-immunotherapy.

Abstract

Rationale: A promising dye for phototheranostics, IR-1048 is a near-infrared region II (NIR-II) cyanine dye that exhibits exceptional optical characteristics in NIR-II spectrum. Unfortunately, the biological applications of IR-1048 are challenged by its hydrophobic nature, the formation of face-to-face stacked dimeric aggregates (H-aggregates) that result in pronounced spectral blue shifts, and issues related to fluorescence quenching. Method: We present a novel docking strategy involving bovine serum albumin (BSA) and lactoferrin (Lf) to construct BSA@IR-1048 and Lf@IR-1048 nanoprobes. The NIR-II optical characteristics of these nanoprobes have been thoroughly investigated through both theoretical and experimental approaches. In addition, we conducted in vitro and in vivo evaluations of their NIR-II photothermal and photodynamic properties, multimodal imaging capabilities, and effectiveness in photoimmunotherapy. Results: Following the protein docking process, both BSA@IR-1048 and Lf@IR-1048 probes exhibited a red-shifted absorbance peak and an "ON" state in NIR-II fluorescence. Theoretical analyses alongside experimental results indicate that Lf@IR-1048, which has a higher docking binding energy of -10.83 kcal/mol, significantly enhances optical characteristics in the NIR-II region. Notably, when utilizing a single NIR-II light source, Lf@IR-1048 was effective in producing single-linear state oxygen and converting photons into heat energy, achieving a photo-thermal conversion efficiency of 41.9%. The overexpression of transferrin receptors in tumor cells also improved tumor-targeting and enrichment capabilities of Lf@IR-1048, as demonstrated vitro and in vivo studies. Comparatively, Lf@IR-1048 facilitated multimodal imaging-guided NIR-II phototherapy, showing an impressive tumor development inhibition rate of 94.8%. Furthermore, in bilateral CT26 tumor-bearing mice, the Lf@IR-1048-based photo-immunotherapy exhibited significant antitumor activity, attributed to enhanced dendritic cell maturation and infiltration of cytotoxic T lymphocytes. Conclusion: Lf@IR-1048 displays a powerful combination of photothermal therapy, photodynamic therapy, and tumor-targeting potential for effective multimodal imaging-guided NIR-II phototherapy, leading to substantial inhibition of tumor growth.